Lenacapavir is emerging as one of the most significant advances in HIV prevention in decades. Trial results suggest the shot can reduce the risk of HIV infection to an exceptionally low level, raising hopes that it could reshape how the disease is prevented.
But the science is only part of the story. The larger challenge now is whether people can actually get the drug, especially in the Latin American countries where it was tested. In those places, many of the people who could benefit most may not be able to afford it.
That gap between medical progress and real-world access is becoming the central issue around lenacapavir. A treatment can look transformative in clinical trials, yet still fall short if price, supply, and health system barriers prevent it from reaching patients at scale.
The result is a crucial test for the next phase of HIV prevention. Lenacapavir may have the potential to dramatically cut new infections, but its impact will depend on whether affordability and distribution problems are solved in the communities where the need is greatest.
